Antagonists of growth hormone-releasing hormone in oncology

Andrew V. Schally, Jozsef L. Varga

Research output: Contribution to journalReview articlepeer-review

45 Scopus citations


The development of antagonists of growth hormone (GH) - releasing hormone (GH-RH) is reviewed. GH-RH antagonists bind with a high affinity to pituitary receptors for GH-RH and inhibit the release of GH in vitro and in vivo. The main applications of GH-RH antagonists would be for tumor therapy. The antitumor effects of GH-RH antagonists are exerted in part indirectly through the inhibition of the secretion of pituitary GH and the reduction in the levels of hepatic insulin like growth factor (IGF-I). However, principal effects of the GH-RH antagonists are exerted directly on tumors. Antagonists of GH-RH inhibit the proliferation of various cancer cell lines in vitro and suppress in vivo the levels and the expression of mRNA for IGF-I and IGF-II in tumors. In many human cancers, the effects of GH-RH antagonists appear to be due to the blockade of the action of tumoral GH-RH. GH-RH ligand is present in various human cancers indicating that it may be an autocrine/paracrine growth factor. Splice variants (SVs) of GH-RH receptors and pituitary type of GH-RH receptors that might mediate effects of tumoral GH-RH and of GH-RH antagonists were demonstrated in many human cancers. This suggests the presence of a stimulatory loop based on GH-RH and SVs or pituitary type of GHRH receptors in diverse tumors. It was shown that GH-RH antagonists inhibited the growth of various human cancer lines xenografted into nude mice including mammary, ovarian, endometrial and prostate cancers, small cell lung carcinomas (SCLC) and non-SCLC, renal, pancreatic, gastric and colorectal carcinomas, malignant gliomas, osteosarcomas and Non-Hodgkin's lymphomas. Further development of GH-RH antagonists should lead to potential therapeutic agents for various cancers.

Original languageEnglish (US)
Pages (from-to)163-170
Number of pages8
JournalCombinatorial Chemistry and High Throughput Screening
Issue number3
StatePublished - Mar 1 2006


  • Cancer therapy
  • GH-RH
  • GH-RH receptors
  • Inhibition of pituitary GH release; antitumor activity
  • Receptor splice variants

ASJC Scopus subject areas

  • Chemistry (miscellaneous)
  • Clinical Biochemistry
  • Pharmacology


Dive into the research topics of 'Antagonists of growth hormone-releasing hormone in oncology'. Together they form a unique fingerprint.

Cite this